KB Home
KBH
Ecopetrol
EC
Petroleo Brasileiro SA Petrobras
PBR
Vale SA
VALE
Taylor Morrison Home
TMHC
US Stock MarketDetailed Quotes
CANF Can-Fite BioPharma
- 1.5200
- -0.0500-3.18%
Close Mar 26 16:00 ET
- 1.5195
- -0.0005-0.03%
Post 20:01 ET
9.27MMarket Cap-0.58P/E (TTM)
1.5850High1.5100Low81.04KVolume1.5300Open1.5700Pre Close124.08KTurnover1.33%Turnover RatioLossP/E (Static)6.10MShares4.690052wk High3.73P/B9.26MFloat Cap1.290052wk Low--Dividend TTM6.10MShs Float1419.0000Historical High--Div YieldTTM4.78%Amplitude1.2900Historical Low1.5310Avg Price1Lot Size
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Can-Fite BioPharma Stock Forum
Major Breakthrough: New Oral Psoriasis Drug Enters Final Testing Phase with Dual Regulatory Backing
Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
Monday, 24th March at 9:00 am
The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugs
Ramat Gan, Israel, March 24, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflam...
Ramat Gan, Israel, March 20, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that it...
Can-Fite's veterinary partnership with Vetbiolix represents a strategic expansion into the $3.8 billion companion animal arthritis market, with Piclidenoson now advancing to an advanced clinical study following successful initial results. The move leverages their existing A3 Adenosine Receptor technology platform into veterinary medicine, where development timelines and approval processes are typically accelerated compared to human therapeutics.
The...
Can-Fite's Breakthrough: New Pet Arthritis Drug Targets Massive $3.8B Market Opportunity
Breakthrough: Can-Fite's Piclidenoson Could Be First Drug for Fatal Genetic Disease
3 MINUTES AGO, 9:00 AM EDT
VIA GLOBENEWSWIRE
FDA & EMA approvals for rare genetic diseases are fast and require clinical studies with small number of patients
Ramat Gan, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological ...
Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson
Wednesday, 19th March at 9:00 am
FDA & EMA approvals for rare genetic diseases are fast and require clinical studies with small number of patients
Ramat Gan, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammat...
No comment yet